4-Anilinoquinazoline Derivatives with Epidermal Growth Factor Receptor Inhibitor Activity

Area of Science:

• Medicinal Chemistry
• Oncology
• Pharmacology

Background:

• 4-Anilinoquinazoline derivatives exhibit potent anti-cancer properties.
• Many derivatives function as selective tyrosine kinase inhibitors (TKIs), notably targeting the epidermal growth factor receptor (EGFR).
• EGFR overexpression/mutation in carcinomas drives tumor progression, and acquired resistance limits current EGFR-targeted therapies.

Purpose of the Study:

• To review recent 4-anilinoquinazoline derivatives with demonstrated EGFR inhibitor activity.
• To explore novel anti-cancer agents addressing EGFR-mediated tumor progression and resistance.

Main Methods:

• Literature review of scientific publications.
• Synthesis and assessment of 4-anilinoquinazoline derivatives for anti-tumor bioactivity.
• Analysis of EGFR inhibitory effects and selectivity.

Main Results:

• Identified numerous 4-anilinoquinazoline derivatives with significant EGFR inhibitory potential.
• Highlighted compounds with high selectivity for EGFR.
• Discussed mechanisms of action and structure-activity relationships.

Conclusions:

• 4-Anilinoquinazoline derivatives represent a promising class of small molecules for EGFR-targeted cancer therapy.
• Further research into novel derivatives is crucial for overcoming acquired resistance and improving anti-cancer efficacy.
• These compounds offer a viable strategy for developing next-generation EGFR inhibitors.